Global Avastin (Bevacizumab) Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Avastin (Bevacizumab) Biosimilars Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Avastin (Bevacizumab) is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Avastin (Bevacizumab) Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Avastin (Bevacizumab) Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Avastin (Bevacizumab) Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Avastin (Bevacizumab) Biosimilars key manufacturers include Roche, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm and PharmaPraxis, etc. Roche, Genentech, Pfizer are top 3 players and held % sales share in total in 2022.
Avastin (Bevacizumab) Biosimilars can be divided into Cancers and AMD, etc. Cancers is the mainstream product in the market, accounting for % sales share globally in 2022.
Avastin (Bevacizumab) Biosimilars is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Avastin (Bevacizumab) Biosimilars industry development. In 2022, global % sales of Avastin (Bevacizumab) Biosimilars went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Avastin (Bevacizumab) Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Segment by Type
Cancers
AMD
Hospitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Avastin (Bevacizumab) Biosimilars market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Avastin (Bevacizumab) Biosimilars, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Avastin (Bevacizumab) Biosimilars industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Avastin (Bevacizumab) Biosimilars in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Avastin (Bevacizumab) Biosimilars introduction, etc. Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Avastin (Bevacizumab) Biosimilars market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Avastin (Bevacizumab) Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Avastin (Bevacizumab) Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Avastin (Bevacizumab) Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Avastin (Bevacizumab) Biosimilars key manufacturers include Roche, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm and PharmaPraxis, etc. Roche, Genentech, Pfizer are top 3 players and held % sales share in total in 2022.
Avastin (Bevacizumab) Biosimilars can be divided into Cancers and AMD, etc. Cancers is the mainstream product in the market, accounting for % sales share globally in 2022.
Avastin (Bevacizumab) Biosimilars is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Avastin (Bevacizumab) Biosimilars industry development. In 2022, global % sales of Avastin (Bevacizumab) Biosimilars went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Avastin (Bevacizumab) Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Segment by Type
Cancers
AMD
Segment by Application
Hospitals
Clinics
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Avastin (Bevacizumab) Biosimilars market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Avastin (Bevacizumab) Biosimilars, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Avastin (Bevacizumab) Biosimilars industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Avastin (Bevacizumab) Biosimilars in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Avastin (Bevacizumab) Biosimilars introduction, etc. Avastin (Bevacizumab) Biosimilars Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Avastin (Bevacizumab) Biosimilars market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices